Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.55 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.47 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.47 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.47 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30794841 | 1.00 | EPHX2 (0.55) | EPHX2MAOBNR1I2PPARGHDAC3 | |
| SCHEMBL6085901 | 0.89 | NR1I2 (0.56) | EPHX2MAOBNR1I2PPARGHDAC3 | |
| SCHEMBL30795707 | 0.87 | NR1I2 (0.66) | EPHX2NR1I2PPARGHDAC3HDAC1 | |
| SCHEMBL2769220 | 0.87 | NR1I2 (0.66) | EPHX2NR1I2PPARGHDAC3HDAC1 | |
| SCHEMBL6085060 | 0.87 | KCNQ3 (0.64) | EPHX2MAOBNR1I2PPARGRORC | |
| SCHEMBL31577328 | 0.81 | BRPF1 (0.53) | EPHX2MAOBNR1I2PPARGHDAC3 | |
| SCHEMBL31577283 | 0.79 | EPHX2 (0.49) | EPHX2MAOBNR1I2PPARGHDAC3 | |
| SCHEMBL24071346 | 0.78 | HDAC8 (0.58) | EPHX2NR1I2HDAC3HDAC1HDAC2 | |
| SCHEMBL31577315 | 0.78 | EPHX2 (0.48) | EPHX2MAOBNR1I2PPARGHDAC3 | |
| SCHEMBL6085382 | 0.77 | HDAC3 (0.54) | EPHX2MAOBHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1442016-B1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CHEILJEDANG CORP (KR) | 2010-04-21 | — | — | EP | claimed |
| US-20060264496-A1 | Substituted indoline and indole derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | claimed |
| JP-2006524641-A | — | — | 2006-11-02 | — | — | JP | claimed |
| EP-1631546-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. Lundbeck A/S (DK) | 2006-03-08 | — | — | EP | claimed |
| EP-1442016-A4 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORP (KR) | 2005-05-25 | — | — | EP | claimed |
| WO-2004096767-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | claimed |
| EP-1442016-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | Cheil Jedang Corporation (KR) | 2004-08-04 | — | — | EP | claimed |
| US-6599929-B2 | Cyclooxygenase-2 is induced by inflammatory factors, hormones, growth factors, cytokines etc | CHEIL JEDANG CORPORATION (KR) | 2003-07-29 | — | — | US | claimed |
| US-20030109568-A1 | 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORPORATION (KR) | 2003-06-12 | — | — | US | claimed |
| WO-2003031409-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORPORATION (KR) | 2003-04-17 | — | — | WO | claimed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-1442016-B1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CJ CHEILJEDANG CORP (KR) | 2010-04-21 | — | — | EP | disclosed |
| US-20060264496-A1 | Substituted indoline and indole derivatives | H. LUNDBECK A/S (DK) | 2006-11-23 | — | — | US | disclosed |
| WO-2004096767-A1 | SUSTITUTED INDOLINE AND INDOLE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-11-11 | — | — | WO | disclosed |
| EP-1442016-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | Cheil Jedang Corporation (KR) | 2004-08-04 | — | — | EP | disclosed |
| US-6599929-B2 | Cyclooxygenase-2 is induced by inflammatory factors, hormones, growth factors, cytokines etc | CHEIL JEDANG CORPORATION (KR) | 2003-07-29 | — | — | US | disclosed |
| US-20030109568-A1 | 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor | CHEIL JEDANG CORPORATION (KR) | 2003-06-12 | — | — | US | disclosed |
| WO-2003031409-A1 | 1H-INDOLE DERIVATIVES AS A HIGHLY SELECTIVE CYCLOOXYGENASE-2 INHIBITOR | CHEIL JEDANG CORPORATION (KR) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109568-A1 | 1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor | IDO1, IDO2, PTGS1 | EPHX2 304/4885MAOB 77/4885NR1I2 448/4885 |
| US-20060264496-A1 | Substituted indoline and indole derivatives | IDO1, IDO2, INMT | EPHX2 4540/4885MAOB 31/4885NR1I2 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.